Astellas Venture Management LLC — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another.
BiotechDeep TechHealthtech
Julian Gough(Co-founder)inOwen Rackham(Co-founder)inJose Polo(Co-founder)inDarrin M. Disley(CEO)in
BoardJane Osbourn(Chair)
Co-investorsAhren Innovation CapitalParkwalk Advisors
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.